Official Title
Expanded Access to Risankizumab
Brief Summary

This is an expanded access program (EAP) for eligible participants with Crohn's Disease (CD). This program is designed to provide access to risankizumab, prior to approval by the local regulatory agency, to patients with the highest unmet need and an urgent need for treatment, where risankizumab may prolong survival, prevent occurrence of clinical events associated with significant morbidity and/or mortality, or stabilize a progressive debilitating disease. Availability will depend on a review of the eligibility of the patient and local approval status of risankizumab for CD. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available
Individual Patients
Crohn's Disease
Ulcerative Colitis (UC)

Drug: Risankizumab
Tablet
Other Name: ABBV-066
Other Name: BI 655066

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Contacts

ABBVIE CALL CENTER
847.283.8955
abbvieclinicaltrials@abbvie.com

AbbVie Inc.
Study Director
AbbVie

NCT Number
Keywords
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Crohn Disease
Colitis, Ulcerative